Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
about
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.The impact of structural biology in medicine illustrated with four case studies.The γ c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response.Injectable Polymeric Cytokine-Binding Nanowires Are Effective Tissue-Specific Immunomodulators.
P2860
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Improved cancer immunotherapy ...... tivity to human interleukin-2.
@en
Improved cancer immunotherapy ...... tivity to human interleukin-2.
@nl
type
label
Improved cancer immunotherapy ...... tivity to human interleukin-2.
@en
Improved cancer immunotherapy ...... tivity to human interleukin-2.
@nl
prefLabel
Improved cancer immunotherapy ...... tivity to human interleukin-2.
@en
Improved cancer immunotherapy ...... tivity to human interleukin-2.
@nl
P2093
P2860
P50
P1476
Improved cancer immunotherapy ...... tivity to human interleukin-2.
@en
P2093
Andreas Katopodis
Barbara Brannetti
Emmanuelle Wirth
Gerhard Zenke
Janine Woytschak
Jiri Kovarik
Lukas Sommer
Simone Popp
P2860
P304
P356
10.1126/SCITRANSLMED.AAG3187
P407
P577
2016-11-01T00:00:00Z